Exhibit 99.8

AMENDMENT

of the voluntary public purchase bid in form of a partial bid

by
Deutsche Balaton Biotech AG
Ziegelhäuser Landstrasse 1, 69120 Heidelberg, Germany
(District Court Frankfurt am Main, HRB 111190)
and

DELPHI Unternehmensberatung Aktiengesellschaft
Ziegelhäuser Landstrasse 1, 69120 Heidelberg, Germany
(District Court Mannheim, HRB 705381)

to the shareholders of

Biofrontera AG

Hemmelrather Weg 201, 51377 Leverkusen, Germany
(District Court Cologne, HRB 49717)

for the purchase of up to 500,000 registered no-par shares
in exchange for
payment of a consideration in the amount of now 8.00 Euro
per share of Biofrontera AG

International Securities Identification Number (ISIN) of the shares of Biofrontera AG: DE0006046113

Securities Identification Code (WKN) of the shares of Biofrontera AG: 604611

Table of Contents

The offer document (“ Offer Document ”) for the voluntary public purchase offer (“ Offer ”) of Deutsche Balaton Biotech AG (“ DB Biotech ”) with its registered office in Frankfurt am Main, registered in the commercial register of the local court of Frankfurt am Main under HRB 11190, and DELPHI Unternehmensberatung Aktiengesellschaft (“ DELPHI ”), with its registered office in Heidelberg, registered in the commercial register of the Local Court of Mannheim under HRB 705381 (DB Biotech and DELPHI jointly referred to as “ Bidders ”), to the shareholders of Biofrontera AG with its registered office in Leverkusen, registered in the commercial register of the Local Court of Cologne under HRB 49717 (“ Target Company ” or “ Biofrontera ”) is available on the Internet under https://www.deutschebalatonbiotech.de/erwerbsangebot-biofrontera-2019 since 21 July 2019, also in a non-binding English translation. The subject matter of the Offer is the acquisition of up to 500,000 registered shares of Biofrontera AG with ISIN DE0006046113 and WKN 604611 (“ Biofrontera Shares ”) including all ancillary rights associated therewith at the time of the settlement of the Offer.

In addition, printed copies of the Offer Document as well as a non-binding English translation of the Offer Document are available free of charge from Deutsche Balaton Biotech AG, Ziegelhäuser Landstraße 1, 69120 Heidelberg Germany and can be requested by fax at +49 6221 6492424.

The bid solely refers to Biofrontera Shares. Other securities which refer to Biofrontera Shares are explicitly not part of this purchase bid. In particular, the bid does not refer to American Depositary Shares with ISIN US09075G1058 which represent Biofrontera Shares (“Biofrontera-ADS”) and which are also traded at the Stuttgart stock exchange. Owners of Biofrontera-ADS may not submit them for sale as part of this bid. Owners of Biofrontera-ADS who are looking to accept the bid regarding the underlying Biofrontera Shares must first exchange their Biofrontera-ADS into Biofrontera Shares. Subsequently, these Biofrontera Shares can be submitted for sale in the context of this bid.

On 1 July 2019, the Bidders amended the Offer by publishing it on its website at https://www.deutschebalatonbiotech.de/erwerbsangebot-biofrontera-2019 to the effect that, instead of the previous consideration of 7.20 Euro per Biofrontera Share, they now offer a consideration of 8.00 Euro as a cash payment.

This amendment to the Offer (“ Offer Amendment ”) was published on the Internet pursuant to section 21 para. 1 sentence 1 no. 2, para. 2, section 14 para. 3 sentence 1 WpÜG under

https://www.deutschebalatonbiotech.de/erwerbsangebot-biofrontera-2019.

In addition, printed copies of this Offer Amendment are available free of charge from Deutsche Balaton Biotech AG, Ziegelhäuser Landstraße 1, 69120 Heidelberg Germany and can be requested by fax to +49 6221 6492424. The notice of (i) the internet address at which this Offer Amendment was published and (ii) the availability of printed copies of this Offer Amendment at Deutsche Balaton Biotech AG was published in the Federal Gazette on 4 July 2019.

The following information changes and supplements the Offer and the Offer Document. The Offer Document must be read and interpreted together with this Offer Amendment (together with the Offer according to the Offer Document, the “Amended Offer”). Unless otherwise stated in this Offer Amendment, all provisions contained in the Offer Document shall continue to apply unchanged. Terms which are used as defined terms in this Offer Amendment and which are defined in the Offer Document shall each have the meaning attributed to them in the Offer Document, unless expressly stated otherwise below.

This Offer Amendment will be made in accordance with the laws of the Federal Republic of Germany, in particular Section 21 WpÜG and the Ordinance on the Content of the Offer Document, the Consideration for Acquisition Offers and Mandatory Offers and the Exemption from the Obligation to Publish and Submit an Offer (“WpÜG Bidding Regulations “).

The Amended Offer will – as well as the original Offer - be made in accordance with certain applicable United States securities laws and the applicable exceptions, in particular Rule 14d-1(c) (the “ Tier I Exemption ”) under the Securities Exchange Act of 1934 (“ Securities Exchange Act ”). To the extent the Amended Offer is subject to US securities laws, such laws shall apply exclusively to Biofrontera Shareholders and holders of Biofrontera ADSs who are resident, domiciled or habitually resident in the USA.

The Amended Offer shall not be implemented in accordance with the provisions of other legal systems. As a result, no registrations, approvals or authorisations of this Offer Amendment have been applied for or obtained from securities regulators and are not intended. The Biofrontera Shareholders cannot rely on the fact that they can rely on provisions for the protection of investors under a legal system other than that of the Federal Republic of Germany. Any contract resulting from the acceptance of the Offer as amended by this Offer Amendment shall be governed exclusively by and construed in accordance with the laws of the Federal Republic of Germany.

During the term of the Amended Offer, the Bidders may acquire shares of the Target Company in a manner other than within the framework of the Amended Offer via the stock exchange or off-exchange or conclude corresponding acquisition agreements, provided that this is done in accordance with the applicable German legal provisions, in particular the WpÜG (see also Section 7.6 of the Offer Document). To the extent that the Bidders are obliged to do so under German law, information on relevant acquisitions or acquisition agreements in Germany will be published, also in a non-binding English translation.

The Bidders will promptly submit to the SEC a non-binding English translation of the respective publications together with the announcement as a supplement to the CB form. Pursuant to the requirements of Tier-I exemption, the Bidders will furthermore submit to the SEC a non-binding English translation of the Offer Amendment together with the notice of advice as a supplement to form CB. Information will be available free of charge on the website of the SEC at http://sec.gov. Biofrontera Shareholders and owners of Biofrontera-ADS with residence, domicile or habitual abode in the United States can access a non-binding English translation of the Offer Amendment at the aforementioned Internet address of the Bidders or request such a translation via the aforementioned contact data of DB Biotech.

This Offer Amendmend as well as the Offer Document may be dispatched or distributed without restrictions in the Federal Republic of German, the European Union and in the European Economic Area.

The dispatch or distribution of the Offer Document, this Offer Amendment, a summary or of any other description of the Offer Document as well as the acceptance of the Amended Offer may be subject to legal restrictions outside of the Federal Republic of German, the European Union and of the European Economic Area. With the exception of the publication and the provision of the Offer Document and the Offer Amendment free of charge pursuant to the WpÜG, the Offer Document and the Offer Amendment may therefore be neither directly nor indirectly dispatched, distributed or transferred by third parties outside of the European Union and the European Economic Area where prohibited by applicable foreign provisions or dependent on compliance with regulatory procedures or on the granting of an approval or on other requirements. Persons who come into possession of the Offer Document or the Offer Amendment outside of the Federal Republic of Germany or who are looking to accept the Amended Offer from there are asked to gather information about possibly applicable restrictions outside of the Federal Republic of Germany and to comply with such restrictions. The Bidders do not assume any liabilities that the transfer or dispatch of the Offer Document or the Offer Amendment by third parties or acceptance of the Amended Offer outside of the Federal Republic of Germany, the member states of the European Union and the European Economic Area is reconcilable with the valid provisions in the respective country. The responsibility of the Bidders and the persons acting in concert with the Bidders pursuant to § 2 Para. 5 WpÜG for non-compliance with foreign regulations by third party is explicitly excluded.

Regardless of the information provided above regarding the dispatch and distribution of the Offer Document and the Offer Amendmend, it should be noted that the Amended Offer can be accepted by all Biofrontera Shareholders who own Biofrontera Shares.

On 15 April 2019, Maruho Deutschland GmbH, Leverkusen, published bidding documents for the voluntary public partial purchase bid to the shareholders of Biofrontera for the purchase of up to 4,322,530 Biofrontera Shareholders in exchange for monetary payment in the amount of 6.60 Euro per Biofrontera Share. The partial purchase bid of Maruho Deutschland GmbH (“ Maruho Bid ”) was published at http://www.pharma-offer.de. The original acceptance term of the Maruho Bid running until 20 May 2019 was extended until 24 June 2019 due to the calling of an extraordinary general meeting of Biofrontera AG in the context of the Maruho Bid pursuant to § 16 Para. 3 WpÜG.

Maruho Deutschland GmbH disclosed on 27 May 2019 that the consideration to be paid as part of the Maruho Bid was being increased to 7.20 Euro per Biofrontera Share.

Maruho Deutschland GmbH disclosed on 31 May 2019 that the shares submitted for sale in the context of the Maruho Bid are henceforth being maintained as registered shares and under the ISIN: DE000A2TSBN7 / WKN: A2TSBN.

As this Offer is being submitted during the acceptance term of the Maruho Bid, the Offer submitted by the Bidders is a competing bid pursuant to § 22 WpÜG. This has triggered the following legal consequences specified in § 22 Para. 2 and 3 WpÜG:

The amendment of the Offer by the Bidders now has the following legal consequences with respect to the Maruho Bid:

Biofrontera Shareholders who have accepted the Maruho Bid may withdraw from the agreement until expiry of the acceptance period of the Maruho Bid in analogous application of § 22 para. 3 WpÜG, provided that the agreement was concluded prior to publication of this Offer Amendment. The right of rescission only does not exist if the Maruho Offer is accepted after publication of this Offer Amendment. Biofrontera Shareholders may only declare the right of withdrawal through written declaration within the - possibly extended - acceptance term for this Offer to the securities-related service provider managing their portfolio. The withdrawal will come into effect with the back posting of the Biofrontera Shares submitted for sale after the Maruho Bid (corresponding with the definition of the term in the Maruho Bid, originally ISIN: DE000A2TSHY1 / WKN: A2TSHY; after conversion of the Maruho Bid to registered shares on 31 May 2019 ISIN: DE000A2TSBN7/ WKN: A2TSBN) of the respective withdrawing Biofrontera Shareholder for whom the withdrawal is to be declared by the portfolio-managing securities-related service provider into the original ISIN DE0006046113 / WKN 604611.

All statements, opinions, intentions and statements geared at the future included in this Offer Amendmend are based on the information and plans available to the Bidders on the day of the publication of this Offer Amendment and on certain assumptions of the Bidders at that time. All information of the Bidders regarding Biofrontera is based on generally accessible information sources, unless specified otherwise.

The Offer Amendment includes certain future-oriented statements which express the intentions, view or current expectations of the Bidders regarding possible future events. Such intentions, view and expectations refer to the time of publication of this Offer Amendment. Moreover, such statements are subject to risks and uncertainties which are periodically not part of the sphere of influence of the Bidders. The future-oriented statements included in the Offer Amendment could turn out to be incorrect. Future events and developments may significantly diverge from the future-oriented statements included in the bidding documents.

It is possible that the Bidders modify the intentions and assessments stated in this Offer Amendment after their publication and the signature date of these Offer Amendment.

According to Sections 4.1 and 6.1 of the Offer Document, the consideration for each Biofrontera share was 7.20 Euro in the form of a cash payment.

On 1 July 2019, the bidders decided to increase the consideration to EUR 8.00 per Biofrontera share in the form of a cash payment.

The Bidders now offer the Biofrontera Shareholders to purchase up to 500,000 registered shares of Biofrontera AG (ISIN DE0006046113 / WKN 604611) including all ancillary rights associated therewith at the time of the settlement of the Offer for a payment of

8,00 Euro (in words: eight Euro)

in cash per Biofrontera Share in accordance with the further provisions of the Offer Document and this Offer Amendment.

The WpÜG specifies the regulations regarding adequacy and amount of the consideration for takeover bids and mandatory offers. These are not applicable to the Offer even after the Offer Amendment. The Amended Offer at hand is neither a takeover bid which is geared towards the procurement of control through achievement of a control majority of at least 30% of the voting rights nor is it a mandatory bid as defined by the WpÜG. This Amended Offer is rather a voluntary public purchase bid in the form of a partial purchase bid as defined by § 10 ff. WpÜG through which the Bidders intend to purchase up to 500,000 Biofrontera Shares.

The Bidders of those kinds of voluntary purchase bids are not bound to the provisions of the WpÜG and the WpÜG Bidding Regulations when determining the consideration offered. Consequently, the Bidders are free to determine the amount of the consideration offered.

The Bidders have now determined the consideration to amount to 8.00 Euro per Biofrontera Share. The Bidders did not have a valuation of the Target Company performed pursuant to the principles of execution of company valuations according to the standard IDW S1 by the Institute of Auditors in Germany (Institut der Wirtschaftsprüfer in Deutschland e.V.) or by any other recognized method for valuation.

In the re-assessing the consideration, the Bidders have based their considerations on the development of the share price since publication of their decision on the offered consideration on 31 May 2019, the purchase prices paid for Biofrontera-Shares by the Bidders and persons acting jointly with the Bidders in connection with the previous acquisitions in the last six months prior to the publication of the decision of the Bidders to make this Acquisition Offer on 29 May 2019 and since then.

The Bidders deem the consideration in the amount of 7.20 Euro per Biofrontera Share as appropriate since

and

The Amended Offer will be implemented as described in the Offer Document. The increase in consideration will not result in any changes in the settlement.

Biofrontera-Shareholders who have already accepted the Offer are entitled to withdraw from the Offer, see chapter 9 of this Offer Amendment.

Shareholders who have already accepted the Offer and who wish to receive the increased consideration need not take any action to do so. The increased consideration automatically also benefits the shareholders who accepted the Offer before the Offer Amendmend and thus before the increase in consideration.

The Board and Supervisory Board of the Target Company are required pursuant to § 27 Para. WpÜG to issue a well-founded statement regarding the Offer and regarding any modification of the Offer. This statement must be published by the Board and by the Supervisory Board of Biofrontera always immediately after receipt of bidding documents and their modifications by the Bidders pursuant to § 14 Para. 3 Clause 1 WpÜG.

The total number of shares issued by Biofrontera amounts to 44,632,674. With the assumption that the Bidders will purchase the max. number of 500,000 Biofrontera Shares as part of the Amended Offer, the consideration required for the purchase of 500,000 Biofrontera Shares would amount to a total of 4,000,000.00 Euro. This amount results from the multiplication of the consideration of 8.00 Euro per Biofrontera Share with the total number of the 500,000 Biofrontera Shares covered by the Amended Offer. From the execution of the Amended Offer, the Bidders are expecting no increase of the ancillary transaction charges in the amount of up to 100,000 Euro (“ Ancillary transaction charges ”) which will arise in the context of the technical implementation and settlement of the purchase bid, particularly for the Central Settlement Center. The max. total amount in cash for the purchase of all 500,000 Biofrontera Shares covered by the purchase bid is expected by the Bidders to amount to 4,100,000.00 Euro.

Before the publication of the Offer Amendment, the Bidders have taken the necessary measures to ensure that the required means including ancillary transaction charges are available for the purchase of up to 500,000 Biofrontera Shares at the time the increased consideration is due for payment. The Bidders are financing the cash payment and the ancillary transaction charges for the implementation of the bid as follows:

Under the premise that the max. number of 500,000 Biofrontera Shares are delivered in the context of this purchase bid, 450,000 of the Biofrontera Shares submitted for sale would be transferred to DB Biotech and 50,000 to DELPHI pursuant to the division agreed between the Bidders and specified in Section 5.8 of the bidding documents. For DB Biotech, this would result in a maximum consideration in the amount of 3,600,000.00 Euro and for DELPHI in the amount of 400,000.00 Euro. The ancillary transaction charges will be divided between the Bidders in the same ratio as the Biofrontera Shares submitted for sale so that up to 90,000.00 Euro will be incurred by DB Biotech and up to 10,000.00 Euro by DELPHI. The total costs for DB Biotech would then amount to 3,690,000.00 Euro and to 410,000.00 Euro for DELPHI.

On 24 June 2019, DB Biotech has obtained a further payment in the amount of 900,000.00 Euro in the capital reserve from their parent company, Deutsche Balaton Aktiengesellschaft, additional to the payment described in the Offer Document. Consequently, DB Biotech has more than sufficient means available to implement this bid.

DELPHI will finance the Amended Offer with its own bank credit and constantly available credit lines from banks. DELPHI has a current credit line of up to EUR 8 million with Bethmann-Bank AG and a further current credit line of up to EUR 10 million with Bank Vontobel, Zurich. Both credit lines have not been fully utilised. In addition, DELPHI receives loans from YVAL Idiosynkratische Investments SE, Heidelberg. The majority shareholder of this company is Mr. Wilhelm Zours, who is also the sole CEO of DELPHI. The unused credit lines are sufficient to service DELPHI’s share of the maximum consideration plus the proportionate maximum transaction costs totaling EUR 410,000.

The agreement described in the Offer Document, concluded between the Bidders and Bethmann BanG on 20 June 2019 between the two Bidders and Bethmann Bank AG, according to which the deposited amount will be available for both Bidders to fulfil all obligations arising from the Offer vis-à-vis the Biofrontera Shareholders accepting the Offer shall apply also for the further payment of Deutsche Balaton Ag as described above. In this respect, the statements on the financing of the Offer from the Offer Document are also valid under the premise of an increased consideration of EUR 8.00 per Biofrontera Share.

Bethmann Bank AG with headquarters in Frankfurt am Main, a securities-related service provider independent of the Bidders, has confirmed in the amended financing confirmation dated 4 July 2019 and attached as Annex 1 ,

“that Deutsche Balaton Biotech AG, Frankfurt am Main, and DELPHI Unternehmensberatung Aktiengesellschaft, Heidelberg, have taken all necessary measures to ensure that the means required for complete fulfillment of the amended purchase offer specified above are available at the time payment of the consideration is due.”

Section 13 of the original Offer Document dated 21 June 2019, published on 21 June 2019, describes the expected effects of the completion of the Offer on the net assets, financial position and results of operations of the Bidders. This presentation relates to the originally offered consideration of 7.20 Euro per Biofrontera Share. The consideration now increased to 8.00 Euro per Biofrontera Share means that the expected effects of the completion of the Amended Offer on the net assets, financial position and results of operations of the Bidders may change in part. The effects of the Completion on the net assets, financial position and results of operations of the Bidders are presented below, taking into account the increased consideration. The information contained in this Section 7 of the Offer Amendment is based on the following starting position and assumptions:

The purchase of Biofrontera Shares on the basis of this purchase bid will most likely impact the net asset position and financial standing of DELPHI - solely on the basis of the assumptions listed in Section 13.1 of these bidding documents - as follows:

In case of a full acceptance of the bid, the following changes for the annual report (individual annual statement Commercial Code) of DELPHI would essentially result:

Due to the prior purchase and sale of Biofrontera Shares since 31 December 2018, the post “Financial assets” is increased from 89,025,491.13 Euro by 13,001,090.05 Euro to 102,026,581.18 Euro.

Due to the purchase prices paid for the prior purchases, the post “Cash balance and credit balance with financial institutions” is reduced from 2,745,117.25 Euro by 2,745,117.25 Euro to 0.00 Euro. DELPHI makes use of bank loans and loans from affiliated companies to purchase holdings consistently. Based on the balance sheet situation from 31 December 2018, the post “Other Liabilities”, which includes bank loans, is changed from 3,068,345.04 Euro by 10,255,972.80 Euro to 13,324,317.84 Euro due to prior purchases.

Under the premise of a utilization of the credit line changed by 10,255,972.80 Euro, the interest result of DELPHI would be reduced annually by approx. 130,000.00 Euro, from the refinancing costs agreed at the time of the publication of these bidding documents which follow the money market interest rates plus a negotiated surcharge. Hereby, an interest rate of 1.25% is assumed. Accordingly, the post “Annual Result 2019” would be reduced by 130,000.00 Euro, the post “Other Liabilities” would increase from 13,324,317.84 by 130,000.00 Euro to 13,454,317.84. In case of rising money market interest rates or changing loan conditions throughout the year, the assumed interest charges would be increased accordingly or reduced in case of dropping money market interest rates or improved loan conditions.

In case of a complete execution of the purchase bid, the post “Financial assets” would increase through the purchase of 50,000 Biofrontera Shares from 102,026,581.18 Euro by 410,000 Euro to 102,436,581.18 Euro with the settlement of the purchase bid. The prorated ancillary transaction costs in the amount of 10,000.00 EUR will be activated as ancillary procurement charges. Based on the balance sheet situation from 31 December 2018 and taking the prior purchases into consideration, the post “Other Liabilities” is changed due to the settlement of this bid from 13,454,317.84 Euro by 410,000.00 Euro due to prior purchases to 13,864,317.84 Euro.

Under the premise of a utilization of the credit line changed by 410,000.00 Euro, the interest result of DELPHI would be modified annually by approx. 5,000.00 Euro, from the refinancing costs agreed at the time of the publication of these bidding documents which follow the money market interest rates plus a negotiated surcharge. Hereby, an interest rate of 1.25% is assumed. Accordingly, the post “Annual Result 2019” would be reduced from minus 130,000.00 Euro by further 5,000.00 Euro to minus 135,000.00 Euro, the post “Other Liabilities” would increase from 13,864,317.84 Euro by further 5,000.00 Euro to 13,869,317.84 Euro. In case of rising money market interest rates or changing loan conditions throughout the year, the assumed interest charges would be increased accordingly or reduced in case of dropping money market interest rates or improved loan conditions.

Based on the balance sheet on 31 December 2018 and with consideration of the prior purchases, the equity capital will be reduced from 22,236,767 Euro by 130,000.00 Euro due to the prior purchases and by approx. 5,000.00 Euro due to the implementation of this purchase bid to 22,101,767.93 Euro. The equity capital ratio will be reduced to approx. 19,7% based on the assumptions specified in Section 13.1 of these bidding documents.

The purchase of Biofrontera Shares by DELPHI in the context of this bid will impact the profit and loss statement of DELPHI as follows when taking the invoicing regulations of the Commercial Code as basis:

The purchase of Biofrontera Shares on the basis of this purchase bid will most likely impact the net asset position and financial standing of DB Biotech - solely on the basis of the assumptions listed in Section 13.1 of these bidding documents - as follows:

In case of a full acceptance of the bid, the following changes for the annual report (individual annual statement Commercial Code) of DB Biotech would essentially result:

Due to the prior purchase and sale of Biofrontera Shares since 31 December 2018, the post “Financial assets” is increased from 6,548,797.39 Euro by 19,276.93 Euro to 6,658,074.32 Euro. Due to the purchase prices paid, the post “Cash balance and credit balance with financial institutions” is reduced from 90,238.93 Euro by 19,276.93 Euro to 70,962.00 Euro. Due to the deposit into the capital reserve of DB Biotech performed by Deutsche Balaton Aktiengesellschaft, the parent company of DB Biotech, in the amount of 4,500,000.00 Euro in total the post “Cash balance and credit balance with financial institutions” is increased from 70,962.00 Euro by the same amount to 4,570,962.00.

In case of a complete execution of the purchase bid, the post “Financial assets” would increase through the purchase of 450,000 Biofrontera Shares from 6,568,074.32 Euro by 3,690,000.00 Euro to 10,258,074.32 Euro with the settlement of the purchase bid. At the same time, the post “Cash balance and credit balance with financial institutions” is reduced from 4,570,962.00 Euro by 3,690,000.00 Euro to 880,962.00 Euro. The prorated ancillary transaction costs in the amount of 90,000.00 EUR will be activated as ancillary procurement charges.

In case of a successful implementation of the purchase bid, the total compared to the annual report effective 31 December 2018 will increase from 7,237,456.72 Euro by 4,500,000.00 Euro to 11,737,456.72 Euro.

Based on the financial situation on 31 December 2018 and with consideration of prior purchases and the deposit into the capital reserves, the financial equity capital remains unchanged as a consequence of the implementation of the purchase bid. The equity capital ratio will be reduced to approx. 99.5% based on the assumptions specified in Section 13.1 of these bidding documents.

The purchase of Biofrontera Shares by DB Biotech in the context of this bid will impact the profit and loss statement of DB Biotech as follows when taking the invoicing regulations of the Commercial Code as basis:

The purchase of Biofrontera Shares on the basis of this purchase bid will most likely impact the net asset position and financial standing of the parent company of DB Biotech - solely on the basis of the assumptions listed in Section 13.1 of these bidding documents - as follows:

Essentially, the following changes will take place:

Due to the payments into the capital reserve of DB Biotech, the post “Shares in associated companies” will increase from 134,346.6 Thousand Euro by 4,500.00 Thousand Euro to 138,846.6 Thousand Euro. Due to the prior purchase and sales of Biofrontera Shares since 31 December 2018, the post “Securities of the fixed assets” is reduced from 133,124.9 Thousand Euro by 8,988.1 Thousand Euro 124,136.8 Thousand Euro.

Due to the expended or received purchase prices and the deposit into the capital reserve of DB Biotech, the post “Cash balance and credit balance with financial institutions” is changed from 1,202.3 Thousand Euro by 15,761.3 Thousand Euro to 16,913.6 Thousand Euro. Based on the financial situation effective 31 December 2018, the post “Net profit” is changed from 3,126.1 Thousand Euro by 11,273.2 Thousand Euro due to sales to 14,399.3 Thousand Euro.

No further impact on the net asset position, financial standing and profit situation of Deutsche Balaton Aktiengesellschaft is expected as the implementation of the purchase bid will take place on the level of the Bidders.

Irrespective of the amendment to the Offer, the Acceptance Period which runs until 24:00 hours (local time Frankfurt am Main) on 19 July 2019 remains unchanged.

The increase in consideration constitutes an amendment to the Offer pursuant to section 21 para. 1 no. 2 WpÜG. Pursuant to Section 21 para. 4 WpÜG, the holders of Biofrontera AG shares who have accepted the Offer prior to the publication of the notification of this change in the Offer may withdraw from the Agreement until the expiry of the Acceptance Period. Please refer to Section 4.5 of the Offer Document for details on the exercise of the right of withdrawal.

Important note:

Biofrontera Shareholders who have already validly accepted the Offer of the Bidders and who wish to continue to accept it do not need to exercise their right of withdrawal or take any further action in order to accept the Offer and receive the increased consideration in accordance with the provisions of the Offer Amendment.

Deutsche Balaton Biotech AG, Frankfurt am Main, listed in the trade registry with the District Court Frankfurt am Main under HRB 111190, and DELPHI Unternehmensberatung Aktiengesellschaft, Heidelberg, listed in the trade registry with the District Court Mannheim, HRB 705381, assume the responsibility for the content of these Offer Amendment and declare to the best of their knowledge that information included in the Offer Amendment are correct and no significant information has been omitted.

Exhibit 99.9

Deutsche Balaton Biotech AG (Frankfurt am Main)

DELPHI Unternehmensberatung Aktiengesellschaft (Heidelberg)

Announcement pursuant to § 21 para. 2 sentence 1, § 14 para. 3 sentence 1 number 2
of the German Securities Acquisition and Takeover Act (“WpÜG”)

The offer document (“ Offer Document ”) for the voluntary public purchase offer (“ Offer ”) of Deutsche Balaton Biotech AG (“ DB Biotech ”) with its registered office in Frankfurt am Main, registered in the commercial register of the local court of Frankfurt am Main under HRB 11190, and DELPHI Unternehmensberatung Aktiengesellschaft (“ DELPHI ”), with its registered office in Heidelberg, registered in the commercial register of the Local Court of Mannheim under HRB 705381 (DB Biotech and DELPHI jointly referred to as “ Bidders ”), to the shareholders of Biofrontera AG with its registered office in Leverkusen, registered in the commercial register of the Local Court of Cologne under HRB 49717 (“ Target Company ” or “ Biofrontera ”) is available on the Internet under https://www.deutschebalatonbiotech.de/erwerbsangebot-biofrontera-2019 since 21 July 2019, also in a non-binding English translation. The subject matter of the Offer is the acquisition of up to 500,000 registered shares of Biofrontera AG with ISIN DE0006046113 and WKN 604611 (“ Biofrontera Shares ”) including all ancillary rights associated therewith at the time of the settlement of the Offer.

The bidders announced on 1 July 2019 that the consideration offered within the framework of the Offer would be increased to EUR 8.00 per Biofrontera Share in cash. Otherwise, the Offer remains unchanged. In particular, the deadline for acceptance of the Offer will continue to be 19 July 2019, 24:00 (local time Frankfurt am Main).

The document amending the Offer and updating the Offer Document (“ Offer Amendment ”) is available in a German-language version and in a non-binding English translation from 4 July 2019 on the Internet at the following address

https://www.deutschebalatonbiotech.de/erwerbsangebot-biofrontera-2019.

In addition, printed copies of the Offer Amendment and a non-binding English translation of the Offer Amendment are available free of charge from Deutsche Balaton Biotech AG, Ziegelhäuser Landstraße 1, 69120 Heidelberg Germany and can be requested by fax to +49 6221 6492424.

Heidelberg, 4 July 2019

Deutsche Balaton Biotech AG (Frankfurt am Main)

DELPHI Unternehmensberatung Aktiengesellschaft (Heidelberg)

Hint:

This publication constitutes neither an offer to purchase nor a solicitation of an offer to sell Biofrontera Shares.

The Offer relates only to Biofrontera Shares. Other securities relating to Biofrontera Shares are expressly not the subject of the Offer. In particular, the Offer does not apply to American Depositary Shares with ISIN US09075G1058 representing Biofrontera Shares (“Biofrontera ADS”) which are also traded on the Stuttgart Stock Exchange. Holders of Biofrontera ADSs may not submit them for sale under the Offer. Holders of Biofrontera ADSs who wish to accept the Offer in respect of the Biofrontera Shares underlying the Biofrontera ADSs must first exchange their Biofrontera ADSs for Biofrontera Shares. Thereafter, these Biofrontera Shares may be tendered for sale under the Offer.

In accordance with the requirements of the Tier I Exemption, the Bidders will file with the SEC a non-binding English translation of the Offer Amendment together with this Announcement as a supplement to the CB form. Information will be available free of charge on the SEC’s website at http://sec.gov as soon as it becomes available. Biofrontera Shareholders and holders of Biofrontera ADSs domiciled or habitually resident in the USA may retrieve a non-binding English translation of the Offer Amendment at the above mentioned internet address of the Bidders or request it from Deutsche Balaton Biotech AG via the above mentioned contact details.

It is not intended that this will be carried out as a public offer in accordance with the provisions of any other legal system. With the exception of the measures described to comply with US capital market regulations, no further announcements, registrations, approvals or approvals of the Offer Document or the partial purchase offer have been applied for or initiated outside the Federal Republic of Germany. The same applies to the Offer Amendment.

Exhibit 99.10

Deutsche Balaton Biotech AG (Frankfurt am Main)

DELPHI Unternehmensberatung Aktiengesellschaft (Heidelberg)

Announcement pursuant to Section 23 Para. 1 Clause 1 No. 1 of the German Securities Acquisition and Takeover Act (“WpÜG”)

Deutsche Balaton Biotech AG (“ DB Biotech ”) with its registered office in Frankfurt am Main, business address in 69120 Heidelberg, Ziegelhäuser Landstraße 1, and DELPHI Unternehmensberatung Aktiengesellschaft (“ DELPHI ”) with its registered office in Heidelberg, business adress ibidem (DB Biotech and DELPHI hereinafter jointly referred to as the “ Bidders ”) have published the offer document for their Voluntary Acquisition Offer (“ Acquisition Offer ”) to the shareholders of Biofrontera AG, Leverkusen, (“ Target Company ”) for the acquisition of up to 500,000 registered shares of Biofrontera AG (ISIN DE0006046113 / WKN 604611) (“ Biofrontera Shares ”) against payment of a cash benefit of original EUR 7.20 per share on 21 June 2019. On 1 July 2019, the bidders announced that they would increase the consideration to EUR 8.00 per Biofrontera share. The Offer Amendment and a notice in the Federal Gazette were published on 4 July 2019. The offer document and the Offer Amendment are available on the Internet at

https://www.deutschebalatonbiotech.de/erwerbsangebot-biofrontera-2019.

The period for acceptance of the Acquisition Offer ends on 19 July 2019, 24:00 hours (local time Frankfurt am Main).

Until 05 July 2019, 11:00 a.m. (local time Frankfurt am Main) (“ Reporting Date ”) the Acquisition Offer was accepted for a total of 12,070 (in words: twelve thousand and seventy) Biofrontera Shares. This corresponds to 0.03 % of the share capital and the voting rights of the Target Company.

The Bidders and the persons acting jointly with the Bidders held the following Biofrontera Shares as of the Reporting Date:

The Bidders and the persons acting jointly with the Bidders thus together hold a total of 12,520,799 Biofrontera Shares. This corresponds to approximately 28.05 % of the share capital and voting rights of the Target Company.

The voting rights from Biofrontera Shares held by DB Biotech are attributed to Deutsche Balaton AG, VV Beteiligungen Aktiengesellschaft, DELPHI and Mr Wilhelm K. T. Zours pursuant to Section 30 Para. 1 Clause 1 no. 1, Clause 3 WpÜG.

The voting rights from Biofrontera Shares held by DELPHI are attributed to Mr. Wilhelm K. T. Zours pursuant to Section 30 Para. 1 Clause 1 no. 1, Clause 3 WpÜG.

The voting rights from Biofrontera Shares held by Deutsche Balaton are attributed to VV Beteiligungen Aktiengesellschaft, DELPHI and Mr. Wilhelm K. T. Zours each pursuant to Section 30 Para. 1 Clause 1 No. 1, Clause 3 WpÜG.

The voting rights from Biofrontera Shares held by ABC Beteiligungen AG are attributed to Deutsche Balaton Aktiengesellschaft, VV Beteiligungen Aktiengesellschaft, DELPHI and Mr. Wilhelm K. T. Zours each pursuant to Section 30 Para. 1 Clause 1 No. 1, Clause 3 WpÜG.

The voting rights from Biofrontera Shares held by Sparta AG are attributed to Deutsche Balaton Aktiengesellschaft, VV Beteiligungen Aktiengesellschaft, DELPHI and Mr. Wilhelm K. T. Zours each pursuant to Section 30 Para. 1 Clause 1 No. 1, Clause 3 WpÜG.

The voting rights from Biofrontera Shares held by Prisma Equity AG are attributed to Deutsche Balaton Aktiengesellschaft, VV Beteiligungen Aktiengesellschaft, DELPHI and Mr. Wilhelm K. T. Zours each pursuant to Section 30 Para. 1 Clause 1 No. 1, Clause 3 WpÜG. The Biofrontera Shares held by Prisma Equity AG are being held on a trust basis for DB Biotech and are used to serve the claim of assignment of Biofrontera Shares to which the owners of the stock purchase warrant issued by DB Biotech in 2018 are entitled. For this reason, the Biofrontera Shares held by Prisma Equity AG are also attributed to DB Biotech pursuant to Section 30 Para. 1 Clause 1 No. 2 WpÜG. Due to the allocation to DB Biotech described above, the Biofrontera Shares held by Prisma Equity AG are also attributed to Deutsche Balaton Aktiengesellschaft, VV Beteiligungen Aktiengesellschaft, DELPHI Unternehmensberatung Aktiengesellschaft and Mr Wilhelm K. T. Zours pursuant to Section 30 Para. 1 Clause 1, No. 2, Clause 2 WpÜG.

The voting rights from Biofrontera Shares held by AEE Ahaus-Enscheder AG are attributed to Deutsche Balaton Aktiengesellschaft, VV Beteiligungen Aktiengesellschaft, DELPHI and Mr. Wilhelm K. T. Zours each pursuant to Section 30 Para. 1 Clause 1 No. 1, Clause 3 WpÜG.

The voting rights from Biofrontera Shares held by MARNA Beteiligungen AG are attributed to Deutsche Balaton Aktiengesellschaft, VV Beteiligungen Aktiengesellschaft, DELPHI and Mr. Wilhelm K. T. Zours each pursuant to Section 30 Para. 1 Clause 1 No. 1, Clause 3 WpÜG.

The voting rights from Biofrontera Shares held by Youbisheng Green Paper AG are attributed to Deutsche Balaton Aktiengesellschaft, VV Beteiligungen Aktiengesellschaft, DELPHI and Mr. Wilhelm K. T. Zours each pursuant to Section 30 Para. 1 Clause 1 No. 1, Clause 3 WpÜG.

The voting rights from Biofrontera Shares held by Ming Le Sports AG are attributed to Deutsche Balaton Aktiengesellschaft, VV Beteiligungen Aktiengesellschaft, DELPHI and Mr. Wilhelm K. T. Zours each pursuant to Section 30 Para. 1 Clause 1 No. 1, Clause 3 WpÜG.

The voting rights from Biofrontera Shares held by Heidelberger Beteiligungsholding AG are attributed to ABC Beteiligungen AG, Deutsche Balaton Aktiengesellschaft, VV Beteiligungen Aktiengesellschaft, DELPHI and Mr. Wilhelm K. T. Zours each pursuant to Section 30 Para. 1 Clause 1 No. 1, Clause 3 WpÜG.

The voting rights from Biofrontera Shares held by Strawtec Group AG are attributed to DELPHI and Mr. Wilhelm K. T. Zours each pursuant to Section 30 Para. 1 Clause 1 No. 1, Clause 3 WpÜG.

Consequently, Mr. Wilhelm K.T. Zours is attributed voting rights from a total of 12,520,799 Biofrontera Shares. This corresponds to a share of 28.05 % of the capital stock and voting rights of Biofrontera AG.

The total number of Biofrontera Shares for which the Acquisition Offer has already been accepted as of the Reporting Date, plus the number of Biofrontera Shares directly held by the Bidders and the persons acting in concert with the Bidders as of the Reporting Date, therefore amounts to 12,532,869 Biofrontera Shares, corresponds to approximately 28.08 % of the share capital and voting rights of the Target Company.

In addition to the aforementioned shareholdings, neither the Bidders nor any of the persons acting jointly with the Bidders within the meaning of Section 2 para. 5 WpÜG or their subsidiaries hold shares of the Target Company and no further voting rights from Biofrontera Shares pursuant to Section 30 WpÜG are attributable to them. Instruments within the meaning of Sections 38, 39 of the Securities Trading Act (“WpHG”) are held neither by the Bidders nor by persons acting jointly with the Bidders or their subsidiaries.

This publication is available - at the same time also in a non-binding English translation - as follows:

on the Internet at: https://www.deutschebalatonbiotech.de/erwerbsangebot-biofrontera-2019

on the Internet dated: 05 July 2019

Heidelberg, the 05 July 2019

Deutsche Balaton Biotech AG

DELPHI Unternehmensberatung Aktiengesellschaft

3